Inside TumorSight Risk: What MRI-Based Recurrence Assessment Can and Cannot Tell Clinicians
Dr. Dereck Mush, MD, MBAStephen Gillett
CEO and Chairman, Verily
- Industry
- Precision health and clinical AI
- Based in
- South San Francisco, USA
- Company funding
- Undisclosed
- Region
- North America
Technology executive with leadership roles at Google, Starbucks and Symantec.
Leads Verily's precision health strategy, securing strategic investment from NVIDIA and the CU Healthcare Innovation Fund.
[]
Related on The Signal
Dr. Dereck Mush, MD, MBA
Oracle and AstraZeneca: Bringing Clinical Trials Closer to Care
Dr. Dereck Mush, MD, MBA
Top 25 Cardiologists to Follow on LinkedIn in 2026
Dr. Dereck Mush, MD, MBA
The EHR Dark Data Goldmine: Why Sentence-Level Provenance Is Pharma's New Real-World Evidence Moat
Dr. Dereck Mush, MD, MBAKeep exploring